Ferrer to distribute DiaGenic test in Europe and Latin America
This article was originally published in Clinica
Executive Summary
Personalised medicine specialist Ferrer inCode (Barcelona, Spain) is to become the exclusive distributor of DiaGenic’s ADtect test for early diagnosis of Alzheimer’s disease in 32 countries across Europe and Latin America. Ferrer, which is part of pharmaceutical device group Grupo Ferrer International, will market and sell ADtect in key European markets such as Germany, the Netherlands, France, Spain and Italy. ADtect differs to other Alzheimer’s tests, as it uses peripheral blood as the sample material to provide early, noninvasive diagnosis of the disease. According to Oslo, Norway-based DiaGenic, Alzheimer’s afflicts around 30 million people worldwide and treatment-related costs were estimated at $315bn in 2005.